IC-265 is under clinical development by IACTA Pharmaceuticals and currently in Phase II for Allergic Conjunctivitis. According to GlobalData, Phase II drugs for Allergic Conjunctivitis have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IC-265’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IC-265 is under development for the treatment of keratoconjunctivitis sicca (dry eye), allergic conjunctivitis and uveitis. It acts by targeting tyrosine protein kinase (SYK). It is administered through ophthalmic route.
IACTA Pharmaceuticals overview
IACTA Pharmaceuticals, Inc., a healthcare company engaged in developing and commercializing innovative eyecare products. The company is headquartered in United States.
For a complete picture of IC-265’s drug-specific PTSR and LoA scores, buy the report here.